Rotarix™

Phase 3

MERCK (MRK)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Pneumococcal Infections

View Full Landscape

Drug Information

Target Indication

Pneumococcal Infections

Clinical Trial

NCT04031846

Last updated: 1/16/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA2/21/2006

Rotarix

Rotarix is indicated for the active immunisation of infants aged 6 to 24 weeks for prevention of gastroenteritis due to rotavirus infection. The use of Rotarix should be based on official recommendation.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

MRK

MERCK

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

EstrogensPhase 3

Infertility

EpacadostatPhase 3

Gastric Adenocarcinoma

ezetimibe (plus simvastatin)Phase 3

Atherosclerosis

Golimumab 50 mg SCPhase 3

Arthritis

Ezetimibe + AtorvastatinPhase 3

Hypercholesterolemia

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts